655
Participants
Start Date
June 30, 2015
Primary Completion Date
April 30, 2016
Study Completion Date
May 31, 2016
Omadacycline
Injection for IV dosing; Tablets for oral dosing
Linezolid
Infusion solution for IV dosing; Tablets for oral dosing
Site 201, Zagreb
Site 203, Zagreb
Site 273, Buffalo
Site 256, Augusta
Site 253, Columbus
Site 259, Miami
Site 264, West Palm Beach
Site 261, Mobile
Site 268, Detroit
Site 255, Rapid City
Site 266, Butte
Site 263, Las Vegas
Site 262, Chula Vista
Site 254, La Mesa
Site 258, Oceanside
Site 252, Santa Ana
Site 260, Santa Ana
Site 269, Stockton
Site 257, Springfield
Site 270, Somers Point
Site 104, Pleven
Site 102, Plovdiv
Site 105, Plovdiv
Site 103, Rousse
Site 101, Sofia
Site 205, Slavonski Brod
Site 202, Zagreb
Site 204, Zagreb
Site 207, Athens
Site 211, Athens
Site 208, Thessaloniki
Site 209, Thessaloniki
Site 110, Budapest
Site 111, Budapest
Site 114, Miskolc
Site 113, Szeged
Site 213, Holon
Site 219, Kfar Saba
Site 214, Nazareth
Site 216, Safed
Site 122, Daugavpils
Site 123, Liepāja
Site 124, Rēzekne
Site 120, Riga
Site 121, Riga
Site 234, Cusco
Site 233, Lima
Site 236, Lima
Site 238, Lima
Site 239, Lima
Site 237, Trujillo
Site 130, Bydgoszcz
Site 133, Katowice
Site 131, Lodz
Site 134, Olsztyn
Site 132, Warsaw
Site 141, Bucharest
Site 142, Bucharest
Site 146, Bucharest
Site 144, Cluj-Napoca
Site 140, Craiova
Site 143, Târgu Mureş
Site 145, Timișoara
Site 241, Benoni
Site 244, Thabazimbi
Site 222, Terrassa
Site 221, Barcelona
Site 247, Ankara
Site 246, Trabzon
Site 172, Dnipropetrovsk
Site 173, Dnipropetrovsk
Site 179, Kharkiv
Site 171, Kyiv
Site 170, Lviv
Site 174, Odesa
Site 175, Uzhhorod
Site 178, Vinnytsia
Site 176, Zaporizhia
Lead Sponsor
Paratek Pharmaceuticals Inc
INDUSTRY